Lysophosphatidylinositol signalling and metabolic diseases

Metabolism is a chemical process used by cells to transform food-derived nutrients, such as proteins, carbohydrates and fats, into chemical and thermal energy. Whenever an alteration of this process occurs, the chemical balance within the cells is impaired and this can affect their growth and respon...

Full description

Bibliographic Details
Main Authors:	Ahmad Arifin, Syamsul, Falasca, Marco
Format:	Article
Language:	English English English
Published:	2016
Subjects:	QP Physiology RM283 Endocrinotheraphy
Online Access:	http://irep.iium.edu.my/52928/ http://irep.iium.edu.my/52928/ http://irep.iium.edu.my/52928/ http://irep.iium.edu.my/52928/1/metabolites-06-00006.pdf http://irep.iium.edu.my/52928/7/52928_Lysophosphatidylinositol_WOS.pdf http://irep.iium.edu.my/52928/13/52928_Lysophosphatidylinositol%20signalling_scopus.pdf

id	iium-52928
recordtype	eprints
spelling	iium-529282017-10-20T07:17:03Z http://irep.iium.edu.my/52928/ Lysophosphatidylinositol signalling and metabolic diseases Ahmad Arifin, Syamsul Falasca, Marco QP Physiology RM283 Endocrinotheraphy Metabolism is a chemical process used by cells to transform food-derived nutrients, such as proteins, carbohydrates and fats, into chemical and thermal energy. Whenever an alteration of this process occurs, the chemical balance within the cells is impaired and this can affect their growth and response to the environment, leading to the development of a metabolic disease. Metabolic syndrome, a cluster of several metabolic risk factors such as abdominal obesity, insulin resistance, high cholesterol and high blood pressure, and atherogenic dyslipidaemia, is increasingly common in modern society. Metabolic syndrome, as well as other diseases, such as diabetes, obesity, hyperlipidaemia and hypertension, are associated with abnormal lipid metabolism. Cellular lipids are the major component of cell membranes; they represent also a valuable source of energy and therefore play a crucial role for both cellular and physiological energy homeostasis. In this review, we will focus on the physiological and pathophysiological roles of the lysophospholipid mediator lysophosphatidylinositol (LPI) and its receptor G-protein coupled receptor 55 (GPR55) in metabolic diseases. LPI is a bioactive lipid generated by phospholipase A (PLA) family of lipases which is believed to play an important role in several diseases. Indeed LPI can affect various functions such as cell growth, differentiation and motility in a number of cell-types. Recently published data suggest that LPI plays an important role in different physiological and pathological contexts, including a role in metabolism and glucose homeostasis. 2016-01-01 Article PeerReviewed application/pdf en http://irep.iium.edu.my/52928/1/metabolites-06-00006.pdf application/pdf en http://irep.iium.edu.my/52928/7/52928_Lysophosphatidylinositol_WOS.pdf application/pdf en http://irep.iium.edu.my/52928/13/52928_Lysophosphatidylinositol%20signalling_scopus.pdf Ahmad Arifin, Syamsul and Falasca, Marco (2016) Lysophosphatidylinositol signalling and metabolic diseases. Metabolites, 6 (1). pp. 1-11. ISSN 2218-1989 http://www.mdpi.com/2218-1989/6/1/6 10.3390/metabo6010006
repository_type	Digital Repository
institution_category	Local University
institution	International Islamic University Malaysia
building	IIUM Repository
collection	Online Access
language	English English English
topic	QP Physiology RM283 Endocrinotheraphy
spellingShingle	QP Physiology RM283 Endocrinotheraphy Ahmad Arifin, Syamsul Falasca, Marco Lysophosphatidylinositol signalling and metabolic diseases
description	Metabolism is a chemical process used by cells to transform food-derived nutrients, such as proteins, carbohydrates and fats, into chemical and thermal energy. Whenever an alteration of this process occurs, the chemical balance within the cells is impaired and this can affect their growth and response to the environment, leading to the development of a metabolic disease. Metabolic syndrome, a cluster of several metabolic risk factors such as abdominal obesity, insulin resistance, high cholesterol and high blood pressure, and atherogenic dyslipidaemia, is increasingly common in modern society. Metabolic syndrome, as well as other diseases, such as diabetes, obesity, hyperlipidaemia and hypertension, are associated with abnormal lipid metabolism. Cellular lipids are the major component of cell membranes; they represent also a valuable source of energy and therefore play a crucial role for both cellular and physiological energy homeostasis. In this review, we will focus on the physiological and pathophysiological roles of the lysophospholipid mediator lysophosphatidylinositol (LPI) and its receptor G-protein coupled receptor 55 (GPR55) in metabolic diseases. LPI is a bioactive lipid generated by phospholipase A (PLA) family of lipases which is believed to play an important role in several diseases. Indeed LPI can affect various functions such as cell growth, differentiation and motility in a number of cell-types. Recently published data suggest that LPI plays an important role in different physiological and pathological contexts, including a role in metabolism and glucose homeostasis.
format	Article
author	Ahmad Arifin, Syamsul Falasca, Marco
author_facet	Ahmad Arifin, Syamsul Falasca, Marco
author_sort	Ahmad Arifin, Syamsul
title	Lysophosphatidylinositol signalling and metabolic diseases
title_short	Lysophosphatidylinositol signalling and metabolic diseases
title_full	Lysophosphatidylinositol signalling and metabolic diseases
title_fullStr	Lysophosphatidylinositol signalling and metabolic diseases
title_full_unstemmed	Lysophosphatidylinositol signalling and metabolic diseases
title_sort	lysophosphatidylinositol signalling and metabolic diseases
publishDate	2016
url	http://irep.iium.edu.my/52928/ http://irep.iium.edu.my/52928/ http://irep.iium.edu.my/52928/ http://irep.iium.edu.my/52928/1/metabolites-06-00006.pdf http://irep.iium.edu.my/52928/7/52928_Lysophosphatidylinositol_WOS.pdf http://irep.iium.edu.my/52928/13/52928_Lysophosphatidylinositol%20signalling_scopus.pdf
first_indexed	2023-09-18T21:14:57Z
last_indexed	2023-09-18T21:14:57Z
_version_	1777411499869863936

Lysophosphatidylinositol signalling and metabolic diseases

Similar Items